First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial

First-line systemic therapeutic options for advanced esophageal squamous cell carcinoma (ESCC) are limited. In this multicenter, double-blind phase 3 trial, a total of 551 patients with previously untreated, locally advanced or metastatic ESCC and PD-L1 combined positive score of ≥1 were randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yan, Zhang, Bo, Xin, Dao, Kou, Xiaoge, Tan, Zhenbo, Zhang, Shu, Sun, Meili, Zhou, Jin, Fan, Min, Zhang, Ming, Song, Yongxiang, Li, Suyi, Yuan, Yuan, Zhuang, Wu, Zhang, Jingdong, Zhang, Li, Jiang, Hao, Gu, Kangsheng, Ye, Huangyang, Ke, Ying, Li, Jing, Wang, Qingyu, Zhu, Jun, Huang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941045/
https://www.ncbi.nlm.nih.gov/pubmed/36732627
http://dx.doi.org/10.1038/s41591-022-02179-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941045/
https://www.ncbi.nlm.nih.gov/pubmed/36732627
http://dx.doi.org/10.1038/s41591-022-02179-2

Ejemplares similares